


A multiple myeloma clinical trial



A clinical trial comparing fewer or more treatment injections in older adults with multiple myeloma

MY.13 | NCT06182774

What is the purpose of this trial?

Treatment for multiple myeloma sometimes involves three or four medicines. One of these medicines may be stopped after a few months. The others are continued indefinitely until they stop working, or side effects happen. In this study, we are testing if the injection can be stopped after around 18 months of treatment with no change to how your multiple myeloma is being controlled.



Why is this trial important?

There is a lack of information about the best length of injectable treatment. This study will help us understand if limiting the length of injectable treatment to 18 months is as good as the usual continuous treatment approach. We will also learn if less treatment may reduce side effects like infections and improve quality of life.

Who can participate in this study?

This trial is for:

- People aged 18 years or older with newly diagnosed multiple myeloma who have received at least 18 months of therapy with the usual drugs, and whose disease has responded well.



This trial is not for:

- People with non-secretory multiple myeloma or AL amyloidosis.
- People who are having a stem cell transplant.
- People who have an active and uncontrolled bacterial, fungal, or viral infection within 7 days prior to starting the study.
- People who are pregnant or breastfeeding.



SHARE THIS SUMMARY WITH YOUR HEALTH CARE TEAM
TO SEE IF THIS TRIAL IS A GOOD OPTION FOR YOU.

What are the risks?



If you choose to take part in this study, there is a risk that stopping the treatment injection after 18 months may not be as good as the standard continuous combination drug therapy. There are risks of side effects, but these risks are anticipated to be no greater than for the current standard treatment with the three medicines.

What can I expect?

If you choose to take part in this study, you will be randomly placed in one of two groups. One group will continue to receive the same treatment they are already on, with injections and tablets. One group will stop the injection at around 18 months, continuing only on the tablets they are already taking. In this study, you will also be asked to complete a few questionnaires at different times to understand your Quality of Life.

How can I find out more or join the study?



Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an *Informed Consent* document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The **MY.13 study** is currently enrolling patients at cancer centres in Canada. For a full list of participating cancer centres please visit www.clinicaltrials.gov and search using NCT06182774.

CLINICAL TRIAL SPONSOR

Canadian Cancer
Trials Group



Groupe canadien
des essais sur le cancer